Aakash Babu has covered the pharmaceutical sector since 2018, starting his career at Reuters, where he specialised in tackling company news. Just before joining the Citeline team, he worked as a healthcare analyst at the Economist Group, focusing on disease trends, drug development, regulatory changes and pharmaceutical pricing. He has a master’s in economics and a post-graduate specialisation in business journalism from Asian College of Journalism-Bloomberg. He was a key member of the team that covered the initial breakthroughs in COVID-19 vaccine research during his time at Reuters. He also has experience in forecasting regulatory trends, drug approvals and pharmaceutical sales. Outside of work he enjoys traveling, writing and watching football.
Latest from Aakash Babu
The San Francisco, CA-based firm looks to keep its pipeline-in-a-product hopes alive for rezpeg with alopecia areata push.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years.
The compounding industry said the FDA’s “green list” of GLP-1 API imports for compounded drugs validates legitimate compounding pharmacies’ role in the US health system.
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. After exploring the potential of amylin receptor agonists, we now look at myostatins, which analysts expect to generate peak sales of $30bn.
The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.